ABSTRACT
The cervical cancer is the most common gynaecological neoplasma during pregnancy. The average frequency during pregnancy and 1 year post partum is around 1 case per 2 200 pregnancies. The authors present a case of locally advanced cervical cancer (IV stage), diagnosed 30 days after Cesarean section. 5-years survival of this stage is 15%.
Subject(s)
Cervix Uteri/pathology , Uterine Cervical Neoplasms/diagnosis , Uterine Cervical Neoplasms/pathology , Adult , Cervix Uteri/surgery , Cesarean Section , Female , Humans , Neoplasm Invasiveness/diagnosis , Neoplasm Invasiveness/pathology , Neoplasm Staging , Pregnancy , Uterine Cervical Neoplasms/surgeryABSTRACT
The study offers the results from the application of recombinant factor VIIa (NovoSeven) in 19 patients with obstetric or gynaecological problems showing severe haemorrhage of non-surgical origin, which could not be controlled by standard therapy (surgery and resuscitation). Haematological and haemostaseological values as well as final outcome are being monitored. The role of the drug and its special indications in complex urgent treatment of life-threatening bleeding are being discussed. Conclusions. The use of NovoSeven (recombinant factor Vlla) on time and when indicated guarantees rapid and effective haemostasis. Thus laparotomy or relaparotomy can be avoided. If no effect is observed after the application of NovoSeven indicates bleeding from a major blood vessel, demanding laparotomy and surgery. The use of the drug leads to reducing the incidence of blood derivatives transfusions and (being a recombinant product)--no risk of transmissive infections.
